Valuing Pharmaceutical Drug Innovations

Gaurab Aryal,Federico Ciliberto,Leland E. Farmer,Ekaterina Khmelnitskaya
2024-04-13
Abstract:We propose a methodology to estimate the market value of pharmaceutical drugs. Our approach combines an event study with a model of discounted cash flows and uses stock market responses to drug development announcements to infer the values. We estimate that, on average, a successful drug is valued at \$1.62 billion, and its value at the discovery stage is \$64.3 million, with substantial heterogeneity across major diseases. Leveraging these estimates, we also determine the average drug development costs at various stages. Furthermore, we explore applying our estimates to design policies that support drug development through drug buyouts and cost-sharing agreements.
General Economics
What problem does this paper attempt to address?
### Problems the Paper Attempts to Solve This paper aims to propose a systematic approach to estimate the market value of drugs. Specifically, the authors combine the event study method and the discounted cash flows model, using the stock market's reaction to drug development announcements to infer the value of drugs. This approach addresses the following issues: 1. **Challenges in Drug Valuation**: - Lack of specific drug R&D expenditure data. - The drug development process is complex and long-term, making it difficult to directly assess its value. 2. **Support for Policy Making**: - Accurate estimation of drug profitability is crucial for policy choices, such as the Medicare drug price negotiation plan in the 2022 Inflation Reduction Act. - Reliable drug valuation can better determine appropriate incentives for innovators, assess the effectiveness of existing policies, and guide industry decisions. 3. **Estimation of Drug Development Costs**: - Estimating the costs of drug development at different stages provides a basis for policy design, such as supporting drug development through drug buyouts and cost-sharing agreements. ### Main Methods and Findings 1. **Two-Step Valuation Method**: - **Step 1**: Determine the change in the company's market value after the drug development announcement. Use an unrestricted market model to estimate the cumulative abnormal return (CAR) for each announcement and multiply the CAR by market capitalization to obtain the change in the company's market value. - **Step 2**: Based on the weak form of the efficient market hypothesis, assume that the change in the company's market value equals the change in the drug's market value. Adjusting for risk factors, estimate the value of the drug at different stages. 2. **Main Findings**: - On average, the market value of a successful drug is $1.62 billion, with a value of $64.3 million at the discovery stage. - There are significant differences in the value of drugs across different disease areas, such as cancer, rare diseases, and endocrine diseases, with average values of $2.66 billion, $783 million, and $1.53 billion, respectively. - The estimated average cost of drug development is $585.1 million, with the expected cost of clinical trials being $1.243 billion. The costs of clinical trials at different stages are $62 million, $304.8 million, and $410.9 million, respectively. 3. **Policy Applications**: - **Drug Buyout Scheme**: The government can purchase the manufacturing rights of successful drugs and make them publicly available, similar to the patent buyout scheme proposed by Kremer (1998). By implementing this scheme with a small probability, the government can pay the optimal price, and the market will adapt to the new expected value. - **Cost-Sharing Agreement**: The government can provide funding to cover development costs in exchange for the company selling a certain quantity of the drug to the government at a predetermined price after approval. For example, the government can pay $585.1 million in R&D costs at the discovery stage in exchange for the company's commitment to provide a certain quantity of the drug for free at a pre-negotiated price. ### Conclusion By combining the event study and discounted cash flows model, this paper provides a practical method to estimate the market value of drugs, thereby offering important references for policymakers. These valuations not only help optimize social welfare but also ensure that companies have sufficient incentives to invest in R&D.